CDK2 and cancer: For example, our analysis identifies vulnerabilities of TP53-mutant cells to manipulating the activity of the CHK2/CDC25A/CDK2 axis across five different cancer types (Fig. 3d and Supplementary Fig. 9e), echoing prior work on therapeutic interventions on CHKs in TP53-deficient cells (Supplementary Note 1).